Standout Papers

Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis 2024 202639
  1. Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis (2024)
    Tracey G. Simon, Robert M. Wilechansky et al. JAMA

Immediate Impact

58 standout
Sub-graph 1 of 19

Citing Papers

Current status and future trends of the global burden of MASLD
2024 Standout
Epidemiology of metabolic dysfunction-associated steatotic liver disease
2024 Standout
2 intermediate papers

Works of Robert M. Wilechansky being referenced

Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis
2019
Nonalcoholic Fatty Liver Disease and Obesity Treatment
2019

Author Peers

Author Last Decade Papers Cites
Robert M. Wilechansky 149 53 42 71 13 216
Marzyeh Amini 126 33 25 91 12 233
Michail Kokkorakis 77 32 26 68 13 187
Imran Paruk 62 31 42 67 16 197
Amit Kumar 145 90 51 34 19 262
Neven Baršić 139 61 86 60 19 269
Ornella Verrastro 135 46 35 85 14 213
Lukas Binder 181 61 22 117 10 221
Ku-Lang Chang 206 90 46 113 11 274
Dian Shi 89 21 32 68 13 283
Bernadette Vitola 149 65 66 86 23 263

All Works

Loading papers...

Rankless by CCL
2026